T 0025/23 (Bevacizumab for the treatment of ovarian cancer/HOFFMANN LA ROCHE) of 15.01.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T002523.20240115
- Date of decision
- 15 January 2024
- Case number
- T 0025/23
- Petition for review of
- -
- Application number
- 13708435.6
- IPC class
- C07K 16/22A61K 31/337
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Combination therapy for the treatment of ovarian cancer
- Applicant name
- F. Hoffmann-La Roche AG
- Opponent name
- Dehmel & Bettenhausen Patentanwälte PartmbB
Mabxience Research, S.L.
Hoffmann Eitle Patent- und Rechtsanwälte
Partnerschaftsgesellschaft mbB
STADA Arzneimittel AG
Pohlman, Sandra M.
Dr. Reddy's Laboratories Limited
Grünecker Patent- und Rechtsanwälte
PartG mbB
Celltrion Inc.
Amgen Inc. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 113(1)European Patent Convention Art 123(2)European Patent Convention Art 83European Patent Convention R 103(1)(a)Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal 2020 Art 012(6)
- Keywords
- -
- Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The decision under appeal is set aside.
The case is remitted to the opposition division for further prosecution.
The appeal fee is reimbursed.